骨髓增生异常综合征病理生理学中的自身免疫机制及其临床相关性。
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.
作者信息
Barrett A John, Sloand Elaine
机构信息
Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Haematologica. 2009 Apr;94(4):449-51. doi: 10.3324/haematol.2009.006080.
Abstract
Accumulating evidence has shown that marrow failure in some patients with myelodysplastic syndrome is associated with autoimmunity, T-cell mediated myelosuppression and cytokine-induced cytopenias. In this perspective article, Drs. Barrett and Sloand expound on auto-immunity in myelodysplastic syndromes, in particular focusing on what has been learned from study of patients with trisomy 8. See related article on page 496.
摘要
越来越多的证据表明，一些骨髓增生异常综合征患者的骨髓衰竭与自身免疫、T细胞介导的骨髓抑制以及细胞因子诱导的血细胞减少有关。在这篇观点文章中，巴雷特博士和斯隆德博士阐述了骨髓增生异常综合征中的自身免疫，尤其着重介绍了对8号三体综合征患者研究的所得。见第496页相关文章。
相似文献
1
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.
Haematologica. 2009 Apr;94(4):449-51. doi: 10.3324/haematol.2009.006080.
2
Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40-CD40L interactions with T helper cells.
Leukemia. 2007 Dec;21(12):2411-9. doi: 10.1038/sj.leu.2404940. Epub 2007 Sep 6.
3
Immune-induced cytopenia: bone marrow failure syndrome.
Curr Hematol Rep. 2004 May;3(3):178-83.
4
Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment.
Haematologica. 2006 May;91(5):583-4.
5
Immunologic abnormalities in myelodysplastic syndromes.
Hematol Oncol Clin North Am. 1992 Jun;6(3):571-86.
6
The immune landscape of myelodysplastic syndromes.
Crit Rev Oncol Hematol. 2016 Nov;107:90-99. doi: 10.1016/j.critrevonc.2016.08.016. Epub 2016 Sep 7.
7
Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?
Semin Hematol. 2000 Jan;37(1):15-29. doi: 10.1016/s0037-1963(00)90027-1.
8
The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS.
Crit Rev Oncol Hematol. 2019 Oct;142:51-57. doi: 10.1016/j.critrevonc.2019.07.018. Epub 2019 Jul 26.
9
Establishment of a myelodysplastic syndrome (MDS)/secondary AML-derived T lymphoid cell line K2-MDS.
Leuk Res. 2000 Feb;24(2):103-8. doi: 10.1016/s0145-2126(99)00168-x.
10
Expression and function of B7 family molecules on blasts of patients with myelodysplastic syndromes.
J Nippon Med Sch. 2007 Feb;74(1):85-6. doi: 10.1272/jnms.74.85.
引用本文的文献
1
Pleural Effusion in a Patient With Chronic Myelomonocytic Leukemia Treated With Azacitidine.
Cureus. 2025 Jan 26;17(1):e78004. doi: 10.7759/cureus.78004. eCollection 2025 Jan.
2
[Pathogenesis and treatment progression of myelodysplastic syndrome combined with Behçets syndrome].
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2025 Jan 25;54(1):131-139. doi: 10.3724/zdxbyxb-2024-0150.
3
Cranial hypertrophic pachymeningitis with myelodysplastic syndrome.
Heliyon. 2024 Jun 13;10(12):e32973. doi: 10.1016/j.heliyon.2024.e32973. eCollection 2024 Jun 30.
4
Single-cell genomics in acquired bone marrow failure syndromes.
Blood. 2023 Oct 5;142(14):1193-1207. doi: 10.1182/blood.2022018581.
5
Large Vessel Vasculitis as an Initial Manifestation of Acute Myeloid Leukemia: A Case Report.
J Korean Soc Radiol. 2022 Jul;83(4):918-923. doi: 10.3348/jksr.2021.0114. Epub 2022 Jan 6.
6
Modeling regulatory network topology improves genome-wide analyses of complex human traits.
Nat Commun. 2021 May 14;12(1):2851. doi: 10.1038/s41467-021-22588-0.
7
Bone Marrow Failure Syndromes, Overlapping Diseases with a Common Cytokine Signature.
Int J Mol Sci. 2021 Jan 12;22(2):705. doi: 10.3390/ijms22020705.
8
Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?
Cancers (Basel). 2021 Jan 3;13(1):132. doi: 10.3390/cancers13010132.
9
Chronic Myelomonocytic Leukemia Presenting With Polyserositis and Seropositivity for Rheumatoid Arthritis.
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620966863. doi: 10.1177/2324709620966863.
10
Etiological causes of pancytopenia: A report of 137 cases.
Avicenna J Med. 2016 Oct-Dec;6(4):109-112. doi: 10.4103/2231-0770.191447.
本文引用的文献
1
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.
Haematologica. 2009 Apr;94(4):496-506. doi: 10.3324/haematol.13612. Epub 2009 Feb 19.
2
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.
J Clin Oncol. 2008 May 20;26(15):2505-11. doi: 10.1200/JCO.2007.11.9214. Epub 2008 Apr 14.
3
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).
Blood. 2007 Aug 1;110(3):847-50. doi: 10.1182/blood-2007-01-067546. Epub 2007 Apr 5.
4
CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins.
Blood. 2007 Mar 15;109(6):2399-405. doi: 10.1182/blood-2006-01-030643. Epub 2006 Nov 7.
5
Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation.
Cancer Res. 2005 Oct 15;65(20):9132-6. doi: 10.1158/0008-5472.CAN-05-1358.
6
Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.
Blood. 2005 Aug 1;106(3):841-51. doi: 10.1182/blood-2004-05-2017. Epub 2005 Apr 12.
7
Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities.
Blood. 2004 Dec 15;104(13):4210-8. doi: 10.1182/blood-2004-01-0103. Epub 2004 Aug 17.
8
Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease.
Environ Mol Mutagen. 2004;44(1):3-9. doi: 10.1002/em.20024.
9
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
Leukemia. 2004 Mar;18(3):460-5. doi: 10.1038/sj.leu.2403239.
10
Myelodysplastic syndrome.
Hematology Am Soc Hematol Educ Program. 2003:176-99. doi: 10.1182/asheducation-2003.1.176.
Zotero 插件